Longevity Acquisition today filed a preliminary proxy on its proposed merger with 4D pharma. Announced in October, the deal has followed a long and winding road as Longevity in November received a deadline extension from shareholders in exchange for a cash contribution. The SPAC also dealt with Nasdaq compliance issues.
A shareholder vote date is not listed in the preliminary proxy, only a placeholder.
Under terms of the deal, 4D pharma would receive the $14.6 million cash held by Longevity. In addition, 4D pharma would gain the proceeds of warrants to purchase Longevity shares worth up to $23 million. Read more.
